286 related articles for article (PubMed ID: 31155924)
1. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca
Bezzerides VJ; Caballero A; Wang S; Ai Y; Hylind RJ; Lu F; Heims-Waldron DA; Chambers KD; Zhang D; Abrams DJ; Pu WT
Circulation; 2019 Jul; 140(5):405-419. PubMed ID: 31155924
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Denegri M; Bachetti T; Li Y; Colombi B; Napolitano C; Coetzee WA; Priori SG
J Mol Cell Cardiol; 2011 Jan; 50(1):214-22. PubMed ID: 20937285
[TBL] [Abstract][Full Text] [Related]
3. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
[TBL] [Abstract][Full Text] [Related]
4. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.
Di Pasquale E; Lodola F; Miragoli M; Denegri M; Avelino-Cruz JE; Buonocore M; Nakahama H; Portararo P; Bloise R; Napolitano C; Condorelli G; Priori SG
Cell Death Dis; 2013 Oct; 4(10):e843. PubMed ID: 24113177
[TBL] [Abstract][Full Text] [Related]
5. The oxidation-resistant CaMKII-MM281/282VV mutation does not prevent arrhythmias in CPVT1.
Sadredini M; Manotheepan R; Lehnart SE; Anderson ME; Sjaastad I; Stokke MK
Physiol Rep; 2021 Sep; 9(18):e15030. PubMed ID: 34558218
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
[TBL] [Abstract][Full Text] [Related]
7. Exercise training prevents ventricular tachycardia in CPVT1 due to reduced CaMKII-dependent arrhythmogenic Ca2+ release.
Manotheepan R; Danielsen TK; Sadredini M; Anderson ME; Carlson CR; Lehnart SE; Sjaastad I; Stokke MK
Cardiovasc Res; 2016 Aug; 111(3):295-306. PubMed ID: 27161030
[TBL] [Abstract][Full Text] [Related]
8. Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue.
Park SJ; Zhang D; Qi Y; Li Y; Lee KY; Bezzerides VJ; Yang P; Xia S; Kim SL; Liu X; Lu F; Pasqualini FS; Campbell PH; Geva J; Roberts AE; Kleber AG; Abrams DJ; Pu WT; Parker KK
Circulation; 2019 Jul; 140(5):390-404. PubMed ID: 31311300
[TBL] [Abstract][Full Text] [Related]
9. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
[TBL] [Abstract][Full Text] [Related]
10. CaMKII inhibition has dual effects on spontaneous Ca
Sadredini M; Haugsten Hansen M; Frisk M; Louch WE; Lehnart SE; Sjaastad I; Stokke MK
Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H446-H460. PubMed ID: 34270372
[TBL] [Abstract][Full Text] [Related]
11. Calcium-calmodulin kinase II mediates digitalis-induced arrhythmias.
Gonano LA; Sepúlveda M; Rico Y; Kaetzel M; Valverde CA; Dedman J; Mattiazzi A; Vila Petroff M
Circ Arrhythm Electrophysiol; 2011 Dec; 4(6):947-57. PubMed ID: 22009705
[TBL] [Abstract][Full Text] [Related]
12. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
[TBL] [Abstract][Full Text] [Related]
13. Increased Reactive Oxygen Species-Mediated Ca
Liu X; Wang S; Guo X; Li Y; Ogurlu R; Lu F; Prondzynski M; de la Serna Buzon S; Ma Q; Zhang D; Wang G; Cotton J; Guo Y; Xiao L; Milan DJ; Xu Y; Schlame M; Bezzerides VJ; Pu WT
Circulation; 2021 May; 143(19):1894-1911. PubMed ID: 33793303
[TBL] [Abstract][Full Text] [Related]
14. Oxidized CaMKII (Ca
Wang Q; Quick AP; Cao S; Reynolds J; Chiang DY; Beavers D; Li N; Wang G; Rodney GG; Anderson ME; Wehrens XHT
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005682. PubMed ID: 29654126
[TBL] [Abstract][Full Text] [Related]
15. Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca
Ottesen AH; Carlson CR; Eken OS; Sadredini M; Myhre PL; Shen X; Dalhus B; Laver DR; Lunde PK; Kurola J; Lunde M; Hoff JE; Godang K; Sjaastad I; Pettilä V; Stridsberg M; Lehnart SE; Edwards AG; Lunde IG; Omland T; Stokke MK; Christensen G; Røsjø H; Louch WE
Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e007045. PubMed ID: 30943765
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Loaiza R; Benkusky NA; Powers PP; Hacker T; Noujaim S; Ackerman MJ; Jalife J; Valdivia HH
Circ Res; 2013 Jan; 112(2):298-308. PubMed ID: 23152493
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia.
Word TA; Quick AP; Miyake CY; Shak MK; Pan X; Kim JJ; Allen HD; Sibrian-Vazquez M; Strongin RM; Landstrom AP; Wehrens XHT
J Cell Mol Med; 2021 Jun; 25(13):6115-24. PubMed ID: 34110090
[TBL] [Abstract][Full Text] [Related]
18. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
[TBL] [Abstract][Full Text] [Related]
20. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
